‘Impressive’ progression-free survival with lorlatinib in non-small cell lung cancer
CHICAGO, USA. The benefit seen with lorlatinib in the 5-year follow-up data from the CROWN…
0 Comments
Lorlatinib Follow-up Data Show Prolonged Progression-Free Survival in ALK-Positive Advanced Lung Cancer
Pfizer today announced long-term follow-up results from the CROWN study7.8Phase III trial evaluating lorlatinib (▼Lorviqua®),…
0 Comments
★ Trastuzumab deruxtecan demonstrates a median progression-free survival of 13.2 months versus 8.1 with chemotherapy in HER2-low and HER2-ultralow hormone-positive metastatic breast cancer after one or more lines of endocrine therapy
Positive results from the phase 3 DESTINY-Breast06 trial showed that trastuzumab deruxtecan demonstrated a statistically…
0 Comments
★ Five-year follow-up data for lorlatinib show prolonged progression-free survival in ALK-positive advanced lung cancer
Pfizer today announced long-term follow-up results from the CROWN study7.8Phase III trial evaluating lorlatinib (▼Lorviqua®),…
0 Comments